Education Research Current About VU Amsterdam NL
Login as
Prospective student Student Employee
Bachelor Master VU for Professionals
Exchange programme VU Amsterdam Summer School Honours programme VU-NT2 Semester in Amsterdam
PhD at VU Amsterdam Research highlights Prizes and distinctions
Research institutes Our scientists Research Impact Support Portal Creating impact
News Events calendar Woman at the top
Israël and Palestinian regions Culture on campus
Practical matters Mission and core values Entrepreneurship on VU Campus
Organisation Partnerships Alumni University Library Working at VU Amsterdam
Sorry! De informatie die je zoekt, is enkel beschikbaar in het Engels.
This programme is saved in My Study Choice.
Something went wrong with processing the request.
Something went wrong with processing the request.

First patient completes new trial to test Alzheimer’s medication

Share
13 March 2025
The existing HIV medication Efavirenz may potentially also be effective for Alzheimer’s patients, Vrije Universiteit Amsterdam neuroscientist Rik van der Kwant and Amsterdam UMC neurologist Jort Vijverberg discovered. This fall, a clinical trial has begun at Amsterdam UMC, and the first patient has just completed the trial.

Participants are still being recruited. The research is led by Rik van der Kant and Jort Vijverberg (Amsterdam UMC - Alzheimer Center Amsterdam). Van der Kant has been researching new drugs for Alzheimer’s disease for years, using groundbreaking technology that allows him to test hundreds of potential medications simultaneously. 

Promising step  
“I discovered that cholesterol buildup in brain cells of Alzheimer’s patients directly leads to an accumulation of the toxic proteins Tau and Amyloid,” Van der Kant explains. “Efavirenz turned out to be suitable for reversing this buildup. It's very special and unique to be able to do all of this ourselves, within the walls of Amsterdam UMC." Vijverberg is also hopeful. “We are very curious to see how this medication will work in Alzheimer's patients. Of course, we still have to see the results, but I consider it a promising step in the right direction.” 

Participants needed 
The trial is still looking for participants. In total, forty patients are needed to take part in the three-month clinical trial in Amsterdam. Participants can take part if they have been diagnosed with early-stage Alzheimer’s disease, are between 50 and 75 years old, and have a family member or caregiver who can accompany them to the research center visits and answer questions about their health and daily functioning. If participants are unsure whether they want to or are able to take part, they can always register without obligation. Their eligibility to participate will be assessed at a later stage.” 

For more information, visit Efavirenz - Brain Research Center 
 

Contact the VU Press Office

Quick links

Homepage Culture on campus VU Sports Centre Dashboard

Study

Academic calendar Study guide Timetable Canvas

Featured

VUfonds VU Magazine Ad Valvas Digital accessibility

About VU

Contact us Working at VU Amsterdam Faculties Divisions
Privacy Disclaimer Veiligheid Webcolofon Cookies Webarchief

Copyright © 2025 - Vrije Universiteit Amsterdam